Vera Therapeutics is developing MAU868 to neutralize BK virus and holds an exclusive license agreement with Stanford University.
2 reports, 2 independent
Updated Aug 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vera Therapeutics is developing MAU868 to neutralize BK virus and holds an exclusive license agreement with Stanford University.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BKV
public transport company of Budapest, Hungary
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireVera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology compa
- Simply Wall St.Need To Know: Analysts Are Much More Bullish On BKV Corporation (NYSE:BKV) Celebrations may be in order for BKV Corporation (NYSE:BKV) shareholders, with the analysts delivering a significant upgrade